Hertz Stock Hit by Lower Price Targets from Barclays and Jefferies
Analysts flag EBITDA risks, liquidity concerns, and softer used-car values for HTZ.
NOTRELOAD AI
Prince Alwaleed Buys 5% of Lucid Motors Amid Stock Volatility
Saudi billionaire Prince Alwaleed acquires 19.5M shares of Lucid, taking a 5% stake after the stock’s sharp mid-July drop.
Prelude Shares Jump as Incyte Drops Rival JAK2 Drug
Prelude Therapeutics stock rises after Incyte discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal.
FDA Raises Serious Doubts Over Replimune’s RP1 Melanoma Therapy Ahead of Key Panel
FDA briefing docs criticize Replimune’s RP1 trial data, raising doubts over effectiveness and sending shares down ahead of Thursday’s panel.
Repligen Beats Q2 Estimates, Raises 2026 Guidance on Strong Bioprocessing Demand
Repligen posts $204M Q2 revenue (+12%), adjusted EPS of $0.54 beating estimates. Raises FY26 organic growth to 10.5%-13.5% and EPS to $2.03-$2.09.
ProMIS Reports Encouraging Safety and Biomarker Results for Alzheimer’s Candidate PMN310
Blinded six-month interim results show no ARIA-E with PMN310, favorable safety in APOE4 carriers, early biomarker movement, and analyst upgrades.